DNA-based nano-sized systems for pharmaceutical and biomedical applications

Advanced Drug Delivery Reviews

Volumn 62, Issue 6, 2010, Pages 626-632

  Nishikawa, Makiya ^a   Rattanakiat, Sakulrat ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CpG motif; DNA; Drug delivery; Innate immunity; Nano assembly; Toll like receptor

Indexed keywords

CPG MOTIF; INNATE IMMUNITY; NANO-ASSEMBLIES; NANO-ASSEMBLY; TOLL-LIKE RECEPTORS;

BIOLOGY; DNA; DRUG DELIVERY; MATERIALS HANDLING; MOLECULES; VIRUSES;

GENES;

ANTHRACYCLINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; DNA; LIPOSOME; MICROSPHERE; NANOMATERIAL; NANOSPHERE; OLIGONUCLEOTIDE; PLASMID DNA; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 9;

ALLERGIC DISEASE; COMPLEX FORMATION; CYTOKINE PRODUCTION; DNA DEGRADATION; GENE THERAPY; HUMAN; HYDROGEL; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERACTIONS WITH DNA; INTERNALIZATION; MEMBRANE PERMEABILITY; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TISSUE DISTRIBUTION;

ADJUVANTS, IMMUNOLOGIC; DNA; DRUG CARRIERS; HUMANS; MOLECULAR CONFORMATION; NANOPARTICLES; NANOTECHNOLOGY; NUCLEIC ACID CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES;

EID: 77953538298     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.03.006     Document Type: Review

References (95)

1. Roy R.N., Guha B.C. Species difference in regard to the biosynthesis of ascorbic acid. Nature 1958, 182:319-320.
2. Roberts R.G., Bobrow M., Bentley D.R. Point mutations in the dystrophin gene. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2331-2335.
3. Sutherland G.R., Richards R.I. Simple tandem DNA repeats and human genetic disease. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3636-4361.
4. Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat. Rev. Genet. 2001, 2:245-255.
5. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
6. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 1996, 65:101-133.
7. Kunkel T.A., Erie D.A. DNA mismatch repair. Annu. Rev. Biochem. 2005, 74:681-710.
8. Seeman N.C. DNA engineering and its application to nanotechnology. Trends Biotechnol. 1999, 17:437-443.
9. Seeman N.C. At the crossroads of chemistry, biology, and materials: structural DNA nanotechnology. Chem. Biol. 2003, 10:1151-1159.
10. Seeman N.C. DNA in a material world. Nature 2003, 421:427-431.
11. Feldkamp U., Niemeyer C.M. Rational design of DNA nanoarchitectures. Angew. Chem. Int. Ed. Engl. 2006, 45:1856-1876.
12. Condon A. Designed DNA molecules: principles and applications of molecular nanotechnology. Nat. Rev. Genet. 2006, 7:565-575.
13. Simmel F.C. Three-dimensional nanoconstruction with DNA. Angew Chem. Int. Ed. Engl. 2008, 47:5884-5887.
14. Li Y., Tseng Y.D., Kwon S.Y., D'Espaux L., Bunch J.S., McEuen P.L., Luo D. Controlled assembly of dendrimer-like DNA. Nat. Mater. 2004, 3:38-42.
15. Um S.H., Lee J.B., Park N., Kwon S.Y., Umbach C.C., Luo D. Enzyme-catalysed assembly of DNA hydrogel. Nat. Mater. 2006, 5:797-801.
16. Rothemund P.W. Folding DNA to create nanoscale shapes and patterns. Nature 2006, 440:297-302.
17. Goodman R.P., Heilemann M., Doose S., Erben C.M., Kapanidis A.N., Turberfield A.J. Reconfigurable, braced, three-dimensional DNA nanostructures. Nat. Nanotechnol. 2008, 3:93-96.
18. He Y., Ye T., Su M., Zhang C., Ribbe A.E., Jiang W., Mao C. Hierarchical self-assembly of DNA into symmetric supramolecular polyhedral. Nature 2008, 452:198-201.
19. Zhang C., Su M., He Y., Zhao X., Fang P.A., Ribbe A.E., Jiang W., Mao C. Conformational flexibility facilitates self-assembly of complex DNA nanostructures. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10665-10669.
20. Liu W., Wang X., Wang T., Sha R., Seeman N.C. PX DNA triangle oligomerized using a novel three-domain motif. Nano Lett. 2008, 8:317-322.
21. Fujibayashi K., Hariadi R., Park S.H., Winfree E., Murata S. Toward reliable algorithmic self-assembly of DNA tiles: a fixed-width cellular automaton pattern. Nano Lett. 2008, 8:1791-1797.
22. Park S.H., Finkelstein G., LaBean T.H. Stepwise self-assembly of DNA tile lattices using dsDNA bridges. J. Am. Chem. Soc. 2008, 130:40-41.
23. Nadano D., Yasuda t., Kishi K. Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. Clin. Chem. 1993, 39:448-452.
24. Nicot A., Pfaff D.W. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. J. Neurosci. Methods 1997, 71:45-53.
25. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
26. Yasuda K., Ogawa Y., Yamane I., Nishikawa M., Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J. Leukoc. Biol. 2005, 77:71-79.
27. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994, 372:333-335.
28. Crooke S.T. Progress in antisense technology. Annu. Rev. Med. 2004, 55:61-95.
29. Crooke S.T. Antisense strategies. Curr. Mol. Med. 2004, 4:465-487.
30. Grünweller A., Wyszko E., Bieber B., Jahnel R., Erdmann V.A., Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003, 31:3185-3193.
31. Wittung P., Nielsen P.E., Buchardt O., Egholm M., Nordén B. DNA-like double helix formed by peptide nucleic acid. Nature 1994, 368:561-563.
32. Alahari S.K., Dean N.M., Fisher M.H., Delong R., Manoharan M., Tivel K.L., Juliano R.L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1996, 50:808-819.
33. Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 2002, 12:103-128.
34. Brown D.A., Kang S.H., Gryaznov S.M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 1994, 269:26801-26805.
35. Nara E., Masegi M., Hatono T., Hashida M. Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of molecular size on absorption. Pharm. Res. 1992, 9:161-168.
36. Nishikawa M., Hashida M. Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors. Adv. Drug Deliv. Rev. 1999, 40:19-37.
37. Cleaver O., Melton D.A. Endothelial signaling during development. Nat. Med. 2003, 9:661-668.
38. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethyleneimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7297-7301.
39. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 1996, 13:820-831.
40. Mahato R.I., Takakura Y., Hashida M. Development of targeted delivery systems for nucleic acid drugs. J. Drug Target. 1997, 4:337-357.
41. Kakizawa Y., Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. 2002, 54:203-222.
42. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 2002, 54:715-758.
43. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
44. Nishikawa M., Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 2001, 12:861-870.
45. Nishikawa M., Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol. Pharm. Bull. 2002, 25:275-283.
46. Thanaketpaisarn O., Nishikawa M., Yamashita F., Hashida M. Tissue-specific characteristics of in vivo electric gene transfer by tissue and intravenous injection of plasmid DNA. Pharm. Res. 2005, 22:883-891.
47. Kobayashi N., Nishikawa M., Takakura Y. Gene therapy and gene delivery. Drug Delivery: Principles and Applications 2005, 305-319. John Wiley & Sons, Inc. B. Wang, T.J. Siahaan, R. Soltero (Eds.).
48. Hickman M.A., Malone R.W., Lehmann-Bruinsma K., Sih T.R., Knoell D., Szoka F.C., Walzem R., Carlson D.M., Powell J.S. Gene expression following direct injection of DNA into liver. Hum. Gene Ther. 1994, 5:1477-1483.
49. O'Hara A.J., Howell J.M., Taplin R.H., Fletcher S., Lloyd F., Kakulas B., Lochmüller H., Karpati G. The spread of transgene expression at the site of gene construct injection. Muscle Nerve 2001, 24:488-495.
50. Vitravene study group A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 2002, 133:467-474.
51. Fattal E., Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 2006, 58:1203-1223.
52. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
53. Regnier V., Préat V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. 1998, 15:1596-1602.
54. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 1998, 16:867-870.
55. Brand R.M., Iversen P.L. Transdermal delivery of antisense compounds. Adv. Drug Deliv. Rev. 2000, 44:51-57.
56. Garcia-Chaumont C., Seksek O., Grzybowska J., Borowski E., Bolard J. Delivery systems for antisense oligonucleotides. Pharmacol. Ther. 2000, 87:255-277.
57. Lambert G., Fattal E., Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev. 2001, 47:99-112.
58. Pinnaduwage P., Schmitt L., Huang L. Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim. Biophys. Acta 1989, 985:33-37.
59. Wagner E., Plank C., Zatloukal K., Cotten M., Birnstiel M.L. Influenza virus hemagglutinin HA-2N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:7934-7938.
60. Lewis J.G., Lin K.Y., Kothavale A., Flanagan W.M., Matteucci M.D., DePrince R.B., Mook R.A., Hendren R.W., Wagner R.W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3176-3181.
61. Mizuguchi H., Nakagawa T., Nakanishi M., Imazu S., Nakagawa S., Mayumi T. Efficient gene transfer into mammalian cells using fusogenic liposome. Biochem. Biophys. Res. Commun. 1996, 218:402-407.
62. Wagner E. Application of membrane-active peptides for nonviral gene delivery. Adv. Drug Deliv. Rev. 1999, 38:279-289.
63. Kaneda Y. Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems. Expert Opin. Drug Deliv. 2008, 5:221-233.
64. Mulligan R.C. The basic science of gene therapy. Science 1993, 260:926-932.
65. Verma I.M., Somia N. Gene therapy - promises, problems and prospects. Nature 1997, 389:239-242.
66. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 2002, 20:446-448.
67. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409:363-366.
68. Dove A. Antisense and sensibility. Nat. Biotechnol. 2002, 20:121-124.
69. Tomita N., Ogihara T., Morishita R. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr. Drug Targets 2003, 4:603-608.
70. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 2005, 56:555-583.
71. Takagi T., Hashiguchi M., Mahato R.I., Tokuda H., Takakura Y., Hashida M. Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages. Biochem. Biophys. Res. Commun. 1998, 245:729-733.
72. Yoshinaga T., Yasuda K., Ogawa Y., Takakura Y. Efficient uptake and rapid degradation of plasmid DNA by murine dendritic cells via a specific mechanism. Biochem. Biophys. Res. Commun. 2002, 299:389-394.
73. Hisazumi J., Kobayashi N., Nishikawa M., Takakura Y. Significant role of liver sinusoidal endothelial cells in hepatic uptake and degradation of naked plasmid DNA after intravenous injection. Pharm. Res. 2004, 21:1223-1228.
74. Emlen W., Mannik M. Kinetics and mechanisms for removal of circulating single-stranded DNA in mice. J. Exp. Med. 1978, 147:684-699.
75. Emlen W., Mannik M. Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin. Exp. Immunol. 1984, 56:185-192.
76. Gauthier V.J., Tyler L.N., Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J. Immunol. 1996, 156:1151-1156.
77. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 1995, 12:825-830.
78. Kobayashi N., Kuramoto T., Yamaoka K., Hashida M., Takakura Y. Hepatic uptake and gene expression mechanisms following intravenous administration of plasmid DNA by conventional and hydrodynamics-based procedures. J. Pharmacol. Exp. Ther. 2001, 297:853-860.
79. Ishii K.J., Suzuki K., Coban C., Takeshita F., Itoh Y., Matoba H., Kohn L.D., Klinman D.M. Genomic DNA released by dying cells induces the maturation of APCs. J. Immunol. 2001, 167:2602-2607.
80. Skoberne M., Beignon A.S., Bhardwaj N. Danger signals: a time and space continuum. Trends Mol. Med. 2004, 10:251-257.
81. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
82. Licht R., van Bruggen M.C., Oppers-Walgreen B., Rijke T.P., Berden J.H. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum. 2001, 44:1320-1330.
83. Wang B.G., Huang H.Y., Chen Y.C., Bristow R.E., Kassauei K., Cheng C.C., Roden R., Sokoll L.J., Chan D.W., Shih I. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003, 63:3966-3968.
84. Jiang N., Pisetsky D.S. The effect of inflammation on the generation of plasma DNA from dead and dying cells in the peritoneum. J. Leukoc. Biol. 2005, 77:296-302.
85. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Wang Y.H., Su B., Nestle F.O., Zal T., Mellman I., Schröder J.M., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
86. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335-376.
87. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
88. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5:471-484.
89. Smyth M.J., Taniguchi M., Street S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 2000, 165:2665-2670.
90. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., Hughes T.K. The interferons. Mechanisms of action and clinical applications. JAMA 1991, 266:1375-1383.
91. Um S.H., Lee J.B., Kwon S.Y., Li Y., Luo D. Dendrimer-like DNA-based fluorescence nanobarcodes. Nat. Protoc. 2006, 1:995-1000.
92. Nishikawa M., Matono M., Rattanakiat S., Matsuoka N., Takakura Y. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology 2008, 124:247-255.
93. Rattanakiat S., Nishikawa M., Funabashi H., Luo D., Takakura Y. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity. Biomaterials 2009, 30:5701-5706.
94. Roberts T.L., Dunn J.A., Terry T.D., Jennings M.P., Hume D.A., Sweet M.J., Stacey K.J. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J. Immunol. 2005, 175:3569-3576.
95. Trouet A., Deprez-de Campeneere D., De Duve C. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nat. New Biol. 1972, 239:110-112.